The Series C funding was spearheaded by a global strategic investor, with additional investments from Aphelion Cardeation and Unorthodox Ventures. Existing investors, including Engage Venture Partners, JWC Venture, and Features Capital, also participated. Laplace Interventional intends to allocate the raised capital towards the completion of their Early Feasibility Study (EFS) and to pursue approval for a pivotal study.

MINNEAPOLIS, March 16, 2025 — Minnesota-based Laplace Interventional, a medical device company focused on developing transcatheter tricuspid valve technology, announced today the completion of its Series C financing. The round was led by a global strategic investor (identity undisclosed) and included investments from Aphelion Capital, Engage Venture Partners, Unorthodox Ventures, JWC Venture, and Features Capital. The company also announced the appointment of Ned Scheetz, Founding Managing Partner at Aphelion Capital, to its Board of Directors.

Laplace Interventional’s device is designed to improve the quality of life for patients worldwide diagnosed with Tricuspid Regurgitation (TR). The company is developing a prosthetic valve that can be implanted using a minimally invasive procedure, eliminating the need for open-heart surgery and potentially reducing future complications.

“To date, we have treated three patients in the Laplace EFS, and all were discharged within 1-2 days and are recovering well. This was our first experience using a dedicated transcatheter tricuspid valve replacement platform, and we are very impressed with the intuitive deployment, imaging requirements, and overall ease of use of the Laplace system across a range of complex anatomies,” stated Dr. Brandon Jones, Interventional Cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center, Portland, Oregon. Laplace has enrolled 22 patients in the United States, primarily as part of their US EFS Study, and 25 patients globally, with encouraging results.

“This financing round is a significant achievement for the company and further confirms the progress we’ve made over the last several years,” said Ramji Iyer, PhD, Founder and CEO of Laplace Interventional. “We appreciate the continued support of our patients, physicians, and new and existing investors, and we look forward to advancing towards a pivotal trial.” Laplace Interventional plans to use the funds from this round to complete their feasibility study (US EFS and OUS) and to progress towards a pivotal study.

“Aphelion Cardeation, a venture fund created to invest in innovative healthcare products, services, and technologies aligned with the American Heart Association’s mission, is pleased to participate in this financing round,” said Ned Scheetz with Aphelion Capital. “We are inspired by Laplace’s innovative solution for TR and its potential to transform care for millions of patients globally.”

Caution: Laplace Interventional’s device is currently under development and has NOT been approved or cleared by the FDA or any other regulatory agency worldwide.

For more information:
Laplace Interventional

SOURCE Laplace Interventional, Inc.

“`